Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Robert H.I. Andtbacka"'
Autor:
Adam Zong, Lixin Li, Anthony W. Tolcher, Melissa Lynne Johnson, Robert H.I. Andtbacka, Manish R. Patel, Alexander Chung, Drew W. Rasco
Publikováno v:
Regular and young investigator award abstracts.
Background TLR agonists mediate antitumor activity through dendritic cell (DC) activation. Most TLR agonists in development are administered intratumorally allowing for less than 30% of advanced solid tumor to be treated. BDB001 is an intravenously a
Autor:
Céleste Lebbé, Merrick I. Ross, Axel Hauschild, Theodore F. Logan, Robert H.I. Andtbacka, John A. Glaspy, Philip Friedlander, Claus Garbe, Jason Chesney, Omid Hamid, Howard L. Kaufman, Parminder Singh, Jenny J. Kim, Frances A. Collichio, Jennifer Gansert, Mohammed M. Milhem, Lisa Chen, Igor Puzanov
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 36, iss 17
Purpose We evaluated the combination of talimogene laherparepvec plus ipilimumab versus ipilimumab alone in patients with advanced melanoma in a phase II study. To our knowledge, this was the first randomized trial to evaluate addition of an oncolyti
Autor:
Juan C. Paramo, Sajeve S. Thomas, William Schmidt, Pallavi Kumar, Eddy C. Hsueh, Deepti Behl, Vinay Kumar Gupta, Prejesh Philips, Edward C. McCarron, Arvinda Padmanabhan, Adam C. Berger, Daniel Milton, Tawnya L. Bowles, Robert Weber, Jeffrey B Travers, Brendan D. Curti, Suthee Rapisuwon, Robert H.I. Andtbacka, Peter D. Beitsch, Mohammed M. Milhem, Edward A. Levine, John R. Hyngstrom, Suprith Badarinath, Anna Bar, John Keech, Marcus O. Butler, Omid Hamid, Brian R. Gastman, Andrew L. Pecora, Craig L. Slingluff, Takami Sato, J. Thaddeus Beck, Sekwon Jang, Catalin Mihalcioiu, John A. Glaspy, Karl D. Lewis, Shernan G. Holtan, Joël Claveau, Montaser Shaheen, Leonel Hernandez-Aya, Jose Lutzky, Brent A. Blumenstein, Joanna J Peterkin, Svetomir N. Markovic, Sujith Kalmadi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundMost patients with advanced melanomas relapse after checkpoint blockade therapy. Thus, immunotherapies are needed that can be applied safely early, in the adjuvant setting. Seviprotimut-L is a vaccine containing human melanoma antigens, plu
Autor:
Howard L. Kaufman, Kevin S. Gorski, Mohammed M. Milhem, David R. Minor, Jeffrey Chou, Robert H.I. Andtbacka, Ai Li, Igor Puzanov, Michael Chastain, Omid Hamid, Abraham Antonio Anderson, Lisa Chen
Publikováno v:
J Clin Oncol
Purpose Combining immunotherapeutic agents with different mechanisms of action may enhance efficacy. We describe the safety and efficacy of talimogene laherparepvec (T-VEC; an oncolytic virus) in combination with ipilimumab (a cytotoxic T-lymphocyte
Autor:
Olivier Michielin, Josep Malvehy, Olga M. Kuznetsova, Jeffrey Chou, F. Stephen Hodi, Anthony J. Olszanski, Ari M. Vanderwalde, Thomas F. Gajewski, John M. Kirkwood, Jonathan Cebon, David Ross Kaufman, Reinhard Dummer, Igor Puzanov, Eugenio Fernandez, Antoni Ribas, Robert H.I. Andtbacka, Georgina V. Long, Lisa Chen
Publikováno v:
Journal for Immunotherapy of Cancer
Meeting abstracts T-VEC is a herpes simplex virus-1-based oncolytic immunotherapy designed to selectively replicate in tumors, produce GM-CSF, and stimulate antitumor immune responses. OPTiM, a Phase III trial of T-VEC vs GM-CSF in unresectable stage
Autor:
Neil Senzer, Igor Puzanov, Bin Yao, Gerald P. Linette, Lynn E. Spitler, Sanjiv S. Agarwala, Susan Doleman, Troy H. Guthrie, Jason Chesney, Ari M. Vanderwalde, Robert Coffin, Keith A. Delman, Lee D. Cranmer, Kevin J. Harrington, Karl D. Lewis, Gregory A. Daniels, Jennifer Gansert, Jonathan S. Zager, Merrick I. Ross, Brendan D. Curti, Ai Li, Mark R. Middleton, Howard L. Kaufman, Wilson H. Miller, Mohammed M. Milhem, Thomas Amatruda, Yining Ye, Frances A. Collichio, Robert H.I. Andtbacka
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 33(25)
Purpose Talimogene laherparepvec (T-VEC) is a herpes simplex virus type 1–derived oncolytic immunotherapy designed to selectively replicate within tumors and produce granulocyte macrophage colony-stimulating factor (GM-CSF) to enhance systemic anti
Autor:
Jon M. Richards, Mark Grose, Mark B. Faries, Robert H.I. Andtbacka, Brendan D. Curti, Darren R. Shafren, Greg Daniels, Sigrun Hallmeyer
Publikováno v:
Cancer Research. 77:CT114-CT114
Background: CAVATAKTM is a novel bio-selected oncolytic and immunotherapeutic strain of Coxsackievirus A21 (CVA21). In a phase 2 study, intratumoral (i.t.) CVA21 injection of advanced melanoma lesions resulted in increases in tumor immune-cell infilt
Autor:
Sanjiv S. Agarwala, John T. Vetto, Rogerio I. Neves, Robert H.I. Andtbacka, Matthew H. Taylor, Richard S. Ungerleider, Adil Daud, Merrick I. Ross, Maki Tanaka, Aislyn D. Boran, Hung T. Khong, Kenneth F. Grossmann
Publikováno v:
Journal of Clinical Oncology. 34:9543-9543
9543Background: HF10 is a replication-competent oncolytic virus derived from HSV-1. We report on preliminary safety data and antitumor activity of HF10 + ipilimumab (ipi) combination in an ongoing Phase 2 trial in melanoma. Methods: Key entry criteri
Publikováno v:
Cancer Research. 75:B13-B13
Background: The risk of recurrence and death in patients (pts) with stages IIIB to IVM1a melanoma following resection is high. T-VEC is an HSV-1 derived oncolytic immunotherapy designed to selectively replicate in tumors and produce GM-CSF to enhance
Autor:
Jason Chesney, Kevin J. Harrington, Kate Liu, Mark Shilkrut, S. Fourie, Frances A. Collichio, Lydia Dreosti, N.M. Steven, Robert Coffin, John Nemunaitis, Robert H.I. Andtbacka, Ai Li, Thomas Amatruda, Merrick I. Ross, Howard L. Kaufman
Publikováno v:
Annals of Oncology. 25:iv382
Aim: T-VEC is an HSV-1-derived oncolytic immunotherapy designed to selectively replicate in tumors and produce GM-CSF to enhance systemic antitumor immune responses. Compared to GM-CSF alone, T-VEC significantly improved durable response rate (DRR; p